[Role of inhibition of transcription factor forkhead box M1 expression by RNA interference in the proliferation and invasiveness of non-small cell lung cancer cells]
- PMID: 20137699
[Role of inhibition of transcription factor forkhead box M1 expression by RNA interference in the proliferation and invasiveness of non-small cell lung cancer cells]
Abstract
Objective: To investigate the change of proliferation and invasiveness of non-small cell lung cancer (NSCLC) cell lines SPC-A-1, A549 and LTEP-a-2 with forkhead box M1 (FoxM1) expression deficiency.
Methods: A siRNA targeting FoxM1 was designed to deplete the FoxM1 expression of these cell lines and an unrelated siRNA used as control. Real-time RT-PCR and Western blotting were used to examine the FoxM1 expression in mRNA and protein level respectively. Colony assay, wound healing assay and transwell chamber assay were employed to evaluate the colony formation ability and invasiveness of FoxM1 deficient cells.
Results: The designed siRNA could efficiently deplete FoxM1 expression by 83.9%, 83.6% and 88.6% in SPC-A-1, A549 and LTEP-a-2 cell lines respectively. Real-time RT-PCR and Western blot test showed that the FoxM1 protein was also depleted. The colony formation numbers (136.0 +/- 15.5, 87.0 +/- 2.6 and 121.7 +/- 9.4 respectively) and invasion cell numbers (19.2 +/- 2.5, 4.2 +/- 0.8 and 6.2 +/- 1.8 respectively) of FoxM1 deficient SPC-A-1, A549 and LTEP-a-2 cell lines were significantly fewer than those of the unrelated-siRNA transfected group (colony formation numbers were 222.3 +/- 20.5, 164.7 +/- 14.1 and 260.7 +/- 13.5 respectively, and invasive cell numbers were 81.4 +/- 6.2, 39.2 +/- 4.6 and 35.6 +/- 3.0 respectively, all P < 0.01). The cell migration rate of siFoxM1 deficient SPC-A-1 (52.6% +/- 7.8%) was significantly lower than that of the unrelated-siRNA transfected group (85.3% +/- 18.6%, P < 0.01).
Conclusions: The proliferation and invasiveness of several NSCLC cell lines were significantly inhibited after the FoxM1 gene expression was depleted. It suggests that inhibiting the FoxM1 expression might be a promising way for lung cancer therapy.
Similar articles
-
[Effects of AG1478 on the expression of FOXM1 gene via FOXO3a in non-small cell lung cancer cells].Zhonghua Zhong Liu Za Zhi. 2013 Aug;35(8):572-8. Zhonghua Zhong Liu Za Zhi. 2013. PMID: 24314213 Chinese.
-
FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.Lung Cancer. 2013 Feb;79(2):173-9. doi: 10.1016/j.lungcan.2012.10.019. Epub 2012 Nov 20. Lung Cancer. 2013. PMID: 23177020
-
MED28 and forkhead box M1 (FOXM1) mediate matrix metalloproteinase 2 (MMP2)-dependent cellular migration in human nonsmall cell lung cancer (NSCLC) cells.J Cell Physiol. 2019 Jul;234(7):11265-11275. doi: 10.1002/jcp.27784. Epub 2018 Nov 29. J Cell Physiol. 2019. PMID: 30499104
-
Targeting FOXM1 in cancer.Biochem Pharmacol. 2013 Mar 1;85(5):644-652. doi: 10.1016/j.bcp.2012.10.013. Epub 2012 Oct 24. Biochem Pharmacol. 2013. PMID: 23103567 Review.
-
Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review.Dis Markers. 2015;2015:352478. doi: 10.1155/2015/352478. Epub 2015 Jul 22. Dis Markers. 2015. PMID: 26451068 Free PMC article. Review.
Cited by
-
Different expression of FoxM1 in human benign and malignant pleural effusion.Med Oncol. 2015 Jan;32(1):312. doi: 10.1007/s12032-014-0312-1. Epub 2014 Dec 10. Med Oncol. 2015. PMID: 25491139
-
FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis.PLoS One. 2013;8(3):e59412. doi: 10.1371/journal.pone.0059412. Epub 2013 Mar 25. PLoS One. 2013. PMID: 23536876 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous